Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery.

In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug.

Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.

[4] Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement).

Thrombocytopenia is a rare but known serious risk characterized by a severe drop in platelets circulating in the blood.